Lundbeck (Schweiz) AG - Abilify Maintena 300 mg, Depot-Injektionssuspension |
| 63177 | | 01 | | Abilify Maintena 300 mg | | Depot-Injektionssuspension | | N05AX12 | | Aripiprazole | | 28.04.2014 | | |
|
Composition |
Praeparatio cryodesiccata: aripiprazolum 300 mg ut aripiprazolum monohydricum, carmellosum natricum, mannitolum, natrii dihydrogenophosphas monohydricus, natrii hydroxidum, pro vitro corresp. natrium max. 1.6 mg.
Solvens (i.m.): aqua ad iniectabile pro vitro.
Corresp. in solutione recenter reconstituta 200 mg pro 1 mL. |
Packungsbestandteile |
| in solutione recenter reconstituta 200 mg pro 1 mL | | | | BAG: Active Agent | Dose |
---|
Aripiprazole | 300 mg |
|
| in solutione recenter reconstituta 200 mg pro 1 mL | | | | BAG: Active Agent | Dose |
---|
Aripiprazole | 300 mg |
|
| Praeparatio cryodesiccata: | | | Depot-Injektionssuspension | | | | | | Active Agent | Dose |
---|
Aripiprazole | 300 mg |
| BAG: Active Agent | Dose |
---|
Aripiprazole | 300 mg |
| | Inactive agents |
---|
Carmellose Sodium | Mannitol | Sodium Dihydrogenophosphate Monohydrate | Sodium Hydroxide |
| |
|
Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
---|
003 | Durchstechflasche(n) à 300 mg | 271.72 | 311.95 | B | SL | Yes |
|